{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10mg&page=2", "query": { "intervention": "Dapagliflozin 10mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 45, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10mg&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dapagliflozin+10mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T00:24:48.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT02547935", "title": "A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus, CKD and Albuminuria" ], "interventions": [ { "name": "Dapagliflozin 10 mg", "type": "DRUG" }, { "name": "Saxagliptin 2.5 mg", "type": "DRUG" }, { "name": "Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 459, "start_date": "2015-09-21", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2019-08-21", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 37, "location_summary": "Peoria, Arizona • Chula Vista, California • Concord, California + 34 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "El Centro", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02547935" }, { "nct_id": "NCT06812429", "title": "Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Inflammation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Inflammation" ], "interventions": [ { "name": "Dapagliflozin (DAPA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2024-05-08", "completion_date": "2025-04-05", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06812429" }, { "nct_id": "NCT02419612", "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 444, "start_date": "2015-08-14", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419612" }, { "nct_id": "NCT01662999", "title": "Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 42, "start_date": "2012-08", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662999" }, { "nct_id": "NCT02777073", "title": "Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Victoza", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dapagliflozin 10mg Tab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 43, "start_date": "2016-03-01", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2024-02-29", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02777073" }, { "nct_id": "NCT05989347", "title": "Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Hyperinsulinism", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Dapagliflozin 10mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 20, "start_date": "2024-10-15", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05989347" }, { "nct_id": "NCT03030235", "title": "Dapagliflozin in PRESERVED Ejection Fraction Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Heart Failure With Preserved Systolic Function" ], "interventions": [ { "name": "Dapagliflozin 10Mg Oral Tablet", "type": "DRUG" }, { "name": "Dapagliflozin matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint Luke's Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "119 Years", "sex": "ALL", "summary": "19 Years to 119 Years" }, "enrollment_count": 324, "start_date": "2017-03-01", "completion_date": "2021-08-13", "has_results": true, "last_update_posted_date": "2022-10-19", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 26, "location_summary": "Fairhope, Alabama • Los Angeles, California • Jacksonville, Florida + 21 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030235" }, { "nct_id": "NCT05741658", "title": "The Fontan Dapagliflozin Pilot Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Dapagliflozin 10mg Tab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2023-11-08", "completion_date": "2026-03-10", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05741658" }, { "nct_id": "NCT02981069", "title": "Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2017-12-15", "completion_date": "2023-03-19", "has_results": true, "last_update_posted_date": "2023-07-20", "last_synced_at": "2026-10-06T00:24:48.767Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02981069" } ] }